Atopic dermatitis differential diagnosis: Difference between revisions

Jump to navigation Jump to search
Line 30: Line 30:
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Tenderness
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Tenderness
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |CBC
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Eosinophils
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Serum IgE  
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Serum IgE  
|-
|-
Line 38: Line 38:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Involved areas
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Involved areas
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Pustule
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Pustule
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |WBC
|-
|-
! rowspan="10" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Skin disorders
! rowspan="10" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Skin disorders
! style="background: #DCDCDC; padding: 5px; text-align: center;" |Atopic dermatitis
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Atopic dermatitis]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Epidermal barrier dysfunction
* Epidermal barrier dysfunction
* Immune dysregulation
* [[Immune]] dysregulation
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Incidence is highest during infancy and early childhood.
* [[Incidence]] is highest during [[infancy]] and early childhood.
| align="center" style="background:#F5F5F5;" | Multiple
| align="center" style="background:#F5F5F5;" | Multiple
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 54: Line 53:
* Infiltrated [[erythema]], [[prurigo]], scales and crusts
* Infiltrated [[erythema]], [[prurigo]], scales and crusts
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Young children -Scalp, cheeks amd extensor surface
* Young children -[[Scalp]], [[cheeks]] amd [[extensor]] surface
* Adolescents -flexural areas and buttock-thigh creases
* [[Adolescent|Adolescents]] -flexural areas and buttock-thigh creases
* Adults - facial involvement and skin flexures  
* Adults - facial involvement and skin flexures  
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | –
Line 70: Line 69:


* Infra-auricular and retro-auricular fissuring
* Infra-auricular and retro-auricular fissuring
* Nipple eczema
* Nipple [[eczema]]
* White dermographism
* White dermographism
* Perifollicular accentuation
* Perifollicular accentuation
| align="center" style="background:#F5F5F5;" | Nl to ↑
| align="center" style="background:#F5F5F5;" | Nl to ↑


(Eosinophilia)
([[Eosinophilia|Eosinophilia)]]
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" | ↑
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 82: Line 81:


* [[Hyperkeratosis]]
* [[Hyperkeratosis]]
* Psoriasiform hyperplasia
* Psoriasiform [[hyperplasia]]
* Dyskeratosis
* Dyskeratosis
| colspan="2" align="center" style="background:#F5F5F5;" |
| colspan="2" align="center" style="background:#F5F5F5;" |
Line 92: Line 91:
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Contact dermatitis|Allergic contact dermatitis]]<ref name="pmid19447733">{{cite journal |vauthors=Nosbaum A, Vocanson M, Rozieres A, Hennino A, Nicolas JF |title=Allergic and irritant contact dermatitis |journal=Eur J Dermatol |volume=19 |issue=4 |pages=325–32 |date=2009 |pmid=19447733 |doi=10.1684/ejd.2009.0686 |url=}}</ref>
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Contact dermatitis|Allergic contact dermatitis]]<ref name="pmid19447733">{{cite journal |vauthors=Nosbaum A, Vocanson M, Rozieres A, Hennino A, Nicolas JF |title=Allergic and irritant contact dermatitis |journal=Eur J Dermatol |volume=19 |issue=4 |pages=325–32 |date=2009 |pmid=19447733 |doi=10.1684/ejd.2009.0686 |url=}}</ref>
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Delayed-type hypersensitivity response
* Delayed-type [[hypersensitivity]] response
* Skin inflammation mediated by hapten-specific T cells
* Skin [[inflammation]] mediated by [[Haptens|hapten]]-specific T cells
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |Any
| align="center" style="background:#F5F5F5;" |Any
| align="center" style="background:#F5F5F5;" |May be multiple after 1-2 days of exposure
| align="center" style="background:#F5F5F5;" |May be multiple after 1-2 days of exposure
| align="center" style="background:#F5F5F5;" | Erythematous well-demarcated papules
| align="center" style="background:#F5F5F5;" | Erythematous well-demarcated [[papules]]
| align="center" style="background:#F5F5F5;" | Surrounding the area in contact with the offending agent  
| align="center" style="background:#F5F5F5;" | Surrounding the area in contact with the offending agent  
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |–
Line 106: Line 105:
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Stinging and burning
* Stinging and burning
* Localized swelling
* Localized [[swelling]]
* Lichenified pruritic plaques
* [[Lichenification|Lichenified]] [[Itch|pruritic]] [[plaques]]
| align="center" style="background:#F5F5F5;" |Nl to ↑  
| align="center" style="background:#F5F5F5;" |Nl to ↑  
(Eosinophilia)
([[Eosinophilia]])
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |Nl
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Eosinophilic spongiosis and microvesicles
* [[Eosinophilic]] spongiosis and [[microvesicles]]
* Exocytosis of eosinophils and lymphocytes  
* [[Exocytosis]] of [[eosinophils]] and [[lymphocytes]]
* Chronic - Hyperkeratosis and parakeratosis
* Chronic - [[Hyperkeratosis]] and parakeratosis
| colspan="2" align="center" style="background:#F5F5F5;" |
| colspan="2" align="center" style="background:#F5F5F5;" |
* Contact with allergens in the past 1-2 days
* Contact with allergens in the past 1-2 days
Line 121: Line 120:
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Contact dermatitis|Irritant contact dermatitis]]<ref name="pmid30293200">{{cite journal |vauthors=Bains SN, Nash P, Fonacier L |title=Irritant Contact Dermatitis |journal=Clin Rev Allergy Immunol |volume= |issue= |pages= |date=October 2018 |pmid=30293200 |doi=10.1007/s12016-018-8713-0 |url=}}</ref>
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Contact dermatitis|Irritant contact dermatitis]]<ref name="pmid30293200">{{cite journal |vauthors=Bains SN, Nash P, Fonacier L |title=Irritant Contact Dermatitis |journal=Clin Rev Allergy Immunol |volume= |issue= |pages= |date=October 2018 |pmid=30293200 |doi=10.1007/s12016-018-8713-0 |url=}}</ref>
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Activation of the innate immune system by the pro-inflammatory properties of chemicals
* Activation of the [[innate immune system]] by the pro-[[inflammatory]] properties of chemicals
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" |–
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |Any, more occupational exposure  
| align="center" style="background:#F5F5F5;" |Any, more with occupational exposure  
| align="center" style="background:#F5F5F5;" |Usually single immediately after the exposure
| align="center" style="background:#F5F5F5;" |Usually single immediately after the exposure
| align="center" style="background:#F5F5F5;" | Well-demarcated red patch with a glazed surface
| align="center" style="background:#F5F5F5;" | Well-demarcated red patch with a glazed surface
Line 133: Line 132:
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Swelling, blistering and scaling of the damaged area
* [[Swelling]], [[Blister|blistering]] and scaling of the damaged area
* Dryness
* Dryness
* Thicker skin
* Thicker skin
Line 140: Line 139:
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Spongiosis
* Spongiosis
* Intraepidermal vesicles or bullae
* Intraepidermal [[vesicles]] or bullae
* Necrosis of keratinocytes
* [[Necrosis]] of [[keratinocytes]]
| colspan="2" align="center" style="background:#F5F5F5;" |
| colspan="2" align="center" style="background:#F5F5F5;" |
* Cumulative exposure to irritants
* Cumulative exposure to irritants
Line 154: Line 153:
| align="center" style="background:#F5F5F5;" | Multiple
| align="center" style="background:#F5F5F5;" | Multiple
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Cradle cap - yellowish scales on the scalp
* [[Cradle cap]] - yellowish scales on the [[Scalp rash|scalp]]
* Patchy or diffuse greasy scaling with or without a yellow-red base
* Patchy or diffuse greasy scaling with or without a yellow-red base
* Crusts
* Crusts
Line 164: Line 163:
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Infants:
* Infants:
** Craddle cap (Sclap) - non-inflammatory greasy scales on the scalp
** [[Cradle cap]] (Sclap) - non-inflammatory greasy scales on the scalp
** Asymptomatic
** Asymptomatic
** Self resolving
** Self resolving
Line 171: Line 170:
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Focal parakeratosis and spongiosis in epidermis
* Focal parakeratosis and spongiosis in epidermis
* Psoriasiform hyperplasia
* Psoriasiform [[hyperplasia]]
* Neutrophils at the margins
* [[Neutrophils]] at the margins
| colspan="2" align="center" style="background:#F5F5F5;" |
| colspan="2" align="center" style="background:#F5F5F5;" |
* Stress
* Stress
Line 182: Line 181:
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Psoriasis]]
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Psoriasis]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Keratinocyte hyperproliferation
* [[Keratinocyte]] hyperproliferation
* Dysregulation of the immune system
* Dysregulation of the [[immune system]]
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | Any, 2 peaks of onset 30-39 years and 50-59 years
| align="center" style="background:#F5F5F5;" | Any, 2 peaks of onset 30-39 years and 50-59 years
| align="center" style="background:#F5F5F5;" | Multiple
| align="center" style="background:#F5F5F5;" | Multiple
| align="center" style="background:#F5F5F5;" | Well-circumscribed, pink papules and symmetrically distributed cutaneous plaques with silvery scales
| align="center" style="background:#F5F5F5;" | Well-circumscribed, pink [[papules]] and symmetrically distributed cutaneous [[plaques]] with silvery scales
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
* Scalp
* Scalp
Line 199: Line 198:
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Auspitz sign  (pinpoint bleeding)
* [[Auspitz's sign]] (pinpoint bleeding)
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Epidermal hyperplasia
* [[Epidermal]] [[hyperplasia]]
* Parakeratosis
* Parakeratosis
* Neutrophils microabscesses (Munro microabscesses)
* [[Neutrophils]] microabscesses (Munro microabscesses)
| colspan="2" align="center" style="background:#F5F5F5;" |
| colspan="2" align="center" style="background:#F5F5F5;" |
* Smoking
* Smoking
Line 217: Line 216:
! align="center" style="background:#DCDCDC;" |[[Lichen simplex chronicus|Lichen simplex]] <ref name="pmid28785363">{{cite journal |vauthors=Voicu C, Tebeica T, Zanardelli M, Mangarov H, Lotti T, Wollina U, Lotti J, França K, Batashki A, Tchernev G |title=Lichen Simplex Chronicus as an Essential Part of the Dermatologic Masquerade |journal=Open Access Maced J Med Sci |volume=5 |issue=4 |pages=556–557 |date=July 2017 |pmid=28785363 |pmc=5535688 |doi=10.3889/oamjms.2017.133 |url=}}</ref>[[Lichen simplex chronicus|chronicus]]
! align="center" style="background:#DCDCDC;" |[[Lichen simplex chronicus|Lichen simplex]] <ref name="pmid28785363">{{cite journal |vauthors=Voicu C, Tebeica T, Zanardelli M, Mangarov H, Lotti T, Wollina U, Lotti J, França K, Batashki A, Tchernev G |title=Lichen Simplex Chronicus as an Essential Part of the Dermatologic Masquerade |journal=Open Access Maced J Med Sci |volume=5 |issue=4 |pages=556–557 |date=July 2017 |pmid=28785363 |pmc=5535688 |doi=10.3889/oamjms.2017.133 |url=}}</ref>[[Lichen simplex chronicus|chronicus]]
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Lichenified plaques  and excoriations of lichen simplex chronicus develop secondary to extensive pruritus due to other conditions such as atopic dermatitis, neuropathic pruritus, etc
* Secondary to extensive [[pruritus]] due to other conditions such as [[Atopic dermatitis|atopic dermatitis,]] neuropathic pruritus, etc
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | Any, peak at 30-50 years of age
| align="center" style="background:#F5F5F5;" | Any, peak at 30-50 years of age
| align="center" style="background:#F5F5F5;" | Multiple
| align="center" style="background:#F5F5F5;" | Multiple
| align="center" style="background:#F5F5F5;" | Lichenified and erythematous, pruritic exudative plaque, and excoriations
| align="center" style="background:#F5F5F5;" | [[Lichenification|Lichenified]] and [[erythematous]], [[Itch|pruritic]] [[exudative]] [[Plaques|plaque]], and excoriations
| align="center" style="background:#F5F5F5;" | Scalp, head, neck, hands, arms, and genitals areas
| align="center" style="background:#F5F5F5;" | Scalp, head, neck, hands, arms, and genitals areas
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | –
Line 229: Line 228:
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Color of plaque varies fro, yellow to reddish brown  
* Color of [[Plaques|plaque]] varies from yellow to reddish brown  
* Plaque size can vary between 3X6 cm 6X10 cm areas.
* [[Plaque]] size can vary between 3X6 cm 6X10 cm areas.
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Markedly hyperplastic epidermis  
* Markedly [[Hyperplasia|hyperplastic]] [[epidermis]]
* Irregular hyperkeratosis and parakeratosis  
* Irregular [[hyperkeratosis]] and parakeratosis  
* Thick granular zone
* Thick granular zone
* Acanthosis  
* [[Acanthosis]]
| colspan="2" align="center" style="background:#F5F5F5;" |
| colspan="2" align="center" style="background:#F5F5F5;" |
* Emotional stress
* Emotional stress
Line 251: Line 250:
! align="center" style="background:#DCDCDC;" |[[Ichthyosis vulgaris]]<ref name="pmid23301728">{{cite journal |vauthors=Thyssen JP, Godoy-Gijon E, Elias PM |title=Ichthyosis vulgaris: the filaggrin mutation disease |journal=Br. J. Dermatol. |volume=168 |issue=6 |pages=1155–66 |date=June 2013 |pmid=23301728 |doi=10.1111/bjd.12219 |url=}}</ref>
! align="center" style="background:#DCDCDC;" |[[Ichthyosis vulgaris]]<ref name="pmid23301728">{{cite journal |vauthors=Thyssen JP, Godoy-Gijon E, Elias PM |title=Ichthyosis vulgaris: the filaggrin mutation disease |journal=Br. J. Dermatol. |volume=168 |issue=6 |pages=1155–66 |date=June 2013 |pmid=23301728 |doi=10.1111/bjd.12219 |url=}}</ref>
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Loss of function mutations in the filaggrin gene (''FLG'')
* Loss of function [[mutations]] in the [[Filaggrin|filaggrin gene (''FLG'')]]
* Autosomal dominant inheritance with incomplete penetrance
* [[Autosomal dominant inheritance]] with [[incomplete penetrance]]
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
Line 258: Line 257:
| align="center" style="background:#F5F5F5;" | Multiple
| align="center" style="background:#F5F5F5;" | Multiple
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Xerosis and gray scaling
* [[Xerosis]] and gray [[Ichthyosis|scaling]]
* Palmar hyperlinearity  
* [[Palmar]] hyperlinearity  
* Keratosis pilaris
* [[Keratosis pilaris]]
| align="center" style="background:#F5F5F5;" |  
| align="center" style="background:#F5F5F5;" |  
* Extensor surfaces of the extremities
* Extensor surfaces of the extremities
Line 274: Line 273:
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Reduced keratohyalin granules  
* Reduced keratohyalin [[granules]]
* Perinuclear keratin retractions in granular cells
* [[Perinuclear space|Perinuclear]] [[keratin]] retractions in [[Granule cell|granular]] cells
* Thick stratum corneum  
* Thick [[stratum corneum]]
* Basket-weave pattern of stratum corneum
* Basket-weave pattern of [[stratum corneum]]
| colspan="2" align="center" style="background:#F5F5F5;" |
| colspan="2" align="center" style="background:#F5F5F5;" |
* Dry and cold weather
* Dry and cold weather
Line 289: Line 288:
| align="center" style="background:#F5F5F5;" | Multiple
| align="center" style="background:#F5F5F5;" | Multiple
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Symmetrical  coin-shaped erythematous plaques
* Symmetrical  coin-shaped [[Erythematous rash|erythematous]] [[plaques]]
* Erosions and excoriations
* Erosions and excoriations
* Chronic lesions- central clearing leading to annular lesions
* Chronic lesions- central clearing leading to annular lesions
Line 300: Line 299:
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Chronically lesions result into central clearing leading to annular lesions.
* Chronically [[lesions]] result into central clearing leading to annular lesions.
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Spongiosis
* Spongiosis
* Perivascular lymphocytic infiltrates, with eosinophils and occasional neutrophils
* [[Perivascular cell|Perivascular]] [[lymphocytic]] infiltrates, with [[eosinophils]] and occasional [[neutrophils]]
| colspan="2" align="center" style="background:#F5F5F5;" |
| colspan="2" align="center" style="background:#F5F5F5;" |
* Risk factors:
* Risk factors:
Line 317: Line 316:
|-
|-
! align="center" style="background:#DCDCDC;" |[[Netherton's syndrome]]<ref name="pmid10835624">{{cite journal |vauthors=Chavanas S, Bodemer C, Rochat A, Hamel-Teillac D, Ali M, Irvine AD, Bonafé JL, Wilkinson J, Taïeb A, Barrandon Y, Harper JI, de Prost Y, Hovnanian A |title=Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome |journal=Nat. Genet. |volume=25 |issue=2 |pages=141–2 |date=June 2000 |pmid=10835624 |doi=10.1038/75977 |url=}}</ref>
! align="center" style="background:#DCDCDC;" |[[Netherton's syndrome]]<ref name="pmid10835624">{{cite journal |vauthors=Chavanas S, Bodemer C, Rochat A, Hamel-Teillac D, Ali M, Irvine AD, Bonafé JL, Wilkinson J, Taïeb A, Barrandon Y, Harper JI, de Prost Y, Hovnanian A |title=Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome |journal=Nat. Genet. |volume=25 |issue=2 |pages=141–2 |date=June 2000 |pmid=10835624 |doi=10.1038/75977 |url=}}</ref>
| align="center" style="background:#F5F5F5;" | Autosomal recessive mutations in the serine protease inhibitor of Kazal type 5 gene (''SPINK5), encoding LEKTI'', a serine protease inhibitor
| align="center" style="background:#F5F5F5;" | [[Autosomal recessive]] [[mutations]] in the [[SPINK5|serine protease inhibitor of Kazal type 5 gene (''SPINK5)'']]'', encoding [[LEKTI]]''[[LEKTI|, a serine protease inhibitor]]
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | Affects neonates
| align="center" style="background:#F5F5F5;" | Affects [[neonates]]
| align="center" style="background:#F5F5F5;" | Multiple
| align="center" style="background:#F5F5F5;" | Multiple
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
Line 326: Line 325:
** Congenital ichthyosiform erythroderma
** Congenital ichthyosiform erythroderma
** Trichorrhexis invaginata
** Trichorrhexis invaginata
** Allergic diseases with ↑ serum IgE levels
** [[Atopy|Allergic diseases]] with ↑ serum [[IgE]] levels
* Ichthyosis linearis circumflexa (ILC) - serpiginous plaques with double scale at the margins
* Ichthyosis linearis circumflexa (ILC) - [[serpiginous]] [[plaques]] with double scale at the margins
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Diffuse pattern
* Diffuse pattern
Line 350: Line 349:
| align="center" style="background:#F5F5F5;" | ↑  
| align="center" style="background:#F5F5F5;" | ↑  
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* psoriasiform hyperplasia
* Psoriasiform [[hyperplasia]]
* Reduced granular layer
* Reduced granular layer
* Dyskeratosis,
* Dyskeratosis  
* Dermal inflammatory infiltrate including neutrophils and eosinophils
* [[Dermal]] [[inflammatory]] infiltrate including [[neutrophils]] and [[eosinophils]]
| colspan="2" align="center" style="background:#F5F5F5;" |
| colspan="2" align="center" style="background:#F5F5F5;" |
* Atopic diseases including asthma, atopic dermatitis and allergic rhinitis
* Atopic diseases including asthma, atopic dermatitis and allergic rhinitis
Line 381: Line 380:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infection
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Infection
! align="center" style="background:#DCDCDC;" |[[Molluscum contagiosum]]
! align="center" style="background:#DCDCDC;" |[[Molluscum contagiosum]]
| align="center" style="background:#F5F5F5;" | Molluscum contagiosum virus inoculation through direct skin contact
| align="center" style="background:#F5F5F5;" | [[Molluscum contagiosum]] virus [[inoculation]] through direct skin contact
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
Line 387: Line 386:
| align="center" style="background:#F5F5F5;" | Multiple
| align="center" style="background:#F5F5F5;" | Multiple
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Flesh-colored, dome-shaped papules with a central umbilication
* Flesh-colored, dome-shaped [[papules]] with a central umbilication
* Lesions are 2-5mm in diameter
* Lesions are 2-5mm in diameter
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Face, trunk, antecubital,  popliteal fossae and groin
* Face, trunk, [[Antecubital fossa|antecubital]][[Popliteal fossa|popliteal fossae]] and groin
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | If molluscum contagiosum is acquired as sexually transmitted disease, it involves, groin and genital region.  
| align="center" style="background:#F5F5F5;" | If [[molluscum contagiosum]] is acquired as [[sexually transmitted disease]], it involves, groin and genital region.  
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Keratinocytes containing eosinophilic inclusion bodies (Henderson-Paterson bodies)
* [[Keratinocytes]] containing [[eosinophilic]] [[inclusion bodies]] (Henderson-Paterson bodies)
* H&E stain - inwards indentation of the epidermis  
* [[H&E stain]] - inwards indentation of the [[epidermis]]
| colspan="2" align="center" style="background:#F5F5F5;" |
| colspan="2" align="center" style="background:#F5F5F5;" |
* Often asymptomatic
* Often asymptomatic
Line 410: Line 409:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Immunologic disorders
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Immunologic disorders
! align="center" style="background:#DCDCDC;" |[[Dermatitis herpetiformis]]<ref name="pmid22137227">{{cite journal |vauthors=Kárpáti S |title=Dermatitis herpetiformis |journal=Clin. Dermatol. |volume=30 |issue=1 |pages=56–9 |date=2012 |pmid=22137227 |doi=10.1016/j.clindermatol.2011.03.010 |url=}}</ref>
! align="center" style="background:#DCDCDC;" |[[Dermatitis herpetiformis]]<ref name="pmid22137227">{{cite journal |vauthors=Kárpáti S |title=Dermatitis herpetiformis |journal=Clin. Dermatol. |volume=30 |issue=1 |pages=56–9 |date=2012 |pmid=22137227 |doi=10.1016/j.clindermatol.2011.03.010 |url=}}</ref>
| align="center" style="background:#F5F5F5;" | Autoimmune disorder as a result of gluten sensitivity leading to the formation of IgA antibodies
| align="center" style="background:#F5F5F5;" | [[Autoimmunity|Autoimmune]] disorder as a result of [[gluten sensitivity]] leading to the formation of [[IgA]] antibodies
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
Line 416: Line 415:
| align="center" style="background:#F5F5F5;" | Multiple
| align="center" style="background:#F5F5F5;" | Multiple
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Excoriated papules or plaques and vesicles arranged in a clustered fashion
* Excoriated [[papules]], [[plaques]] and [[vesicles]] arranged in a clustered fashion
* Symmetrical
* Symmetrical
* Erosions and excoriations  
* Erosions and excoriations  
Line 426: Line 425:
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Oral manifestation such as vesicles and erosion may be present
* Oral manifestation such as [[vesicles]] and erosion may be present
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Papillary micro-abscesses
* [[Papillary]] micro-[[abscesses]]
* Sub-epidermal blisters containing neutrophils, eosinophils, and fibrin  
* Sub-epidermal [[blisters]] containing [[neutrophils]], [[eosinophils]], and [[fibrin]]
* Sub-epidermal vacuolization  
* Sub-epidermal [[vacuolization]]
| colspan="2" align="center" style="background:#F5F5F5;" |
| colspan="2" align="center" style="background:#F5F5F5;" |
* Intermittent pruritic papules and vesicles
* Intermittent pruritic papules and vesicles
Line 441: Line 440:
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Wiskott-Aldrich syndrome]]<ref name="pmid24817816">{{cite journal |vauthors=Buchbinder D, Nugent DJ, Fillipovich AH |title=Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments |journal=Appl Clin Genet |volume=7 |issue= |pages=55–66 |date=2014 |pmid=24817816 |pmc=4012343 |doi=10.2147/TACG.S58444 |url=}}</ref>
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Wiskott-Aldrich syndrome]]<ref name="pmid24817816">{{cite journal |vauthors=Buchbinder D, Nugent DJ, Fillipovich AH |title=Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments |journal=Appl Clin Genet |volume=7 |issue= |pages=55–66 |date=2014 |pmid=24817816 |pmc=4012343 |doi=10.2147/TACG.S58444 |url=}}</ref>
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Mutation in the gene encoding for Wiskott-Aldrich syndrome protein (WASp) on the short arm of the X chromosome
* Mutation in the gene encoding for [[Wiskott-Aldrich syndrome]] protein (WASp) on the short arm of the [[X chromosome]]
* X-linked disorder
* [[X linked inheritance|X-linked disorder]]
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | –
Line 448: Line 447:
| align="center" style="background:#F5F5F5;" | Multiple
| align="center" style="background:#F5F5F5;" | Multiple
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Rash is clinically similar to atopic dermatitis
* Rash is clinically similar to [[atopic dermatitis]]
* Erythematous and pruritic lesions
* [[Erythematous]] and [[Itch|pruritic]] lesions
* Lesions can bleed due to thrombocytopenia
* Lesions can bleed due to [[thrombocytopenia]]
* Cutaneous manifestations includes petechiae and ecchymosis
* Cutaneous manifestations includes [[Petechia|petechiae]] and [[ecchymosis]]
| align="center" style="background:#F5F5F5;" | Rash can involve lesions located at the same areas of classical atopic dermatitis:
| align="center" style="background:#F5F5F5;" | Rash can involve lesions located at the same areas of classical atopic dermatitis:


Line 459: Line 458:
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | Infants can present with petechiae, prolonged bleeding from umbilicus or circumcision,  purpura, hematemesis, melena, epistaxis, hematuria  or unusal bruising
| align="center" style="background:#F5F5F5;" | Infants can present with [[petechiae]], prolonged [[bleeding]] from [[umbilicus]] or circumcision,  [[purpura]],[[hematemesis]], [[melena]], [[epistaxis]], [[hematuria]] or unusal bruising
| align="center" style="background:#F5F5F5;" |Nl to ↑
| align="center" style="background:#F5F5F5;" |Nl to ↑


Line 466: Line 465:
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* [[Hyperkeratosis]]
* [[Hyperkeratosis]]
* Psoriasiform hyperplasia
* Psoriasiform [[hyperplasia]]
* Dyskeratosis
* Dyskeratosis


Line 483: Line 482:
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hyper-IgE syndrome]]<ref name="pmid24058807">{{cite journal |vauthors=Mogensen TH |title=STAT3 and the Hyper-IgE syndrome: Clinical presentation, genetic origin, pathogenesis, novel findings and remaining uncertainties |journal=JAKSTAT |volume=2 |issue=2 |pages=e23435 |date=April 2013 |pmid=24058807 |pmc=3710320 |doi=10.4161/jkst.23435 |url=}}</ref>
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Hyper-IgE syndrome]]<ref name="pmid24058807">{{cite journal |vauthors=Mogensen TH |title=STAT3 and the Hyper-IgE syndrome: Clinical presentation, genetic origin, pathogenesis, novel findings and remaining uncertainties |journal=JAKSTAT |volume=2 |issue=2 |pages=e23435 |date=April 2013 |pmid=24058807 |pmc=3710320 |doi=10.4161/jkst.23435 |url=}}</ref>
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Defects in the JAK-STAT signaling pathway leading to dysfunctional T helper cell type 17 (Th17) differentiation
* Defects in the [[JAK-STAT signaling pathway]] leading to dysfunctional [[T helper cell]] type 17 ([[T helper 17 cell|Th17]]) [[differentiation]]
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | –
Line 490: Line 489:
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Papulopustular
* Papulopustular
* Severely pruritic eczematous rash  
* Severely [[Itch|pruritic]] eczematous rash  
* Pustular and may impetiginized
* [[Pustular rash|Pustular]] and may impetiginized
* Lichenification may occur
* [[Lichenification]] may occur
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Face and scalp
* Face and scalp
Line 504: Line 503:
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Characteristic coarse facies
* Characteristic coarse facies
* Increased alar width and broad nasal bridge
* Increased alar width and broad [[nasal bridge]]
* High-arched oral palate
* High-arched oral palate
* Hyperextensible joints  
* Hyperextensible joints  
Line 512: Line 511:
| align="center" style="background:#F5F5F5;" | ↑  
| align="center" style="background:#F5F5F5;" | ↑  
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Eosinophil-rich infiltration around the hair follicles
* [[Eosinophil]]-rich infiltration around the hair follicles
| colspan="2" align="center" style="background:#F5F5F5;" |
| colspan="2" align="center" style="background:#F5F5F5;" |
* Cold abscesses
* Cold abscesses
Line 525: Line 524:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Malignancy
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Malignancy
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Mycosis fungoides]]
! style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Mycosis fungoides]]
| align="center" style="background:#F5F5F5;" | Clonal expansion of CD4<sup>+</sup> memory T cells (CD45RO<sup>+</sup>)
| align="center" style="background:#F5F5F5;" | Clonal expansion of [[CD4+ cell|CD4]]<sup>+</sup> [[memory T cells]] (CD45RO<sup>+</sup>)
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | +
| align="center" style="background:#F5F5F5;" | +
Line 531: Line 530:
| align="center" style="background:#F5F5F5;" | Multiple
| align="center" style="background:#F5F5F5;" | Multiple
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Non pruritic patches and intensely pruritic plaques  
* Non-pruritic patches and intensely [[Itch|pruritic]] [[plaques]]
* Comedones, cysts
* [[Comedones]], [[cysts]]
* Tumors of skin
* [[Tumors]] of skin
* Erythematous macules
* [[Erythematous]] [[macules]]
* Hypopigmented patches  
* [[Hypopigmented area|Hypopigmented]] patches  
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Asymmetrical
* Asymmetrical
Line 544: Line 543:
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" | –
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Alopecia
* [[Alopecia]]
* Acneiform lesions
* [[Acneiform eruption|Acneiform]] lesions
* Plaques size can vary between 2-20 cm
* [[Plaques]] size can vary between 2-20 cm
* Lymphadenopathy
* [[Lymphadenopathy]]
* Children-  hypopigmented patches most common
* Children-  [[Hypopigmentation|hypopigmented]] patches most common
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" | Nl
| align="center" style="background:#F5F5F5;" |
| align="center" style="background:#F5F5F5;" |
* Perifollicular infiltrates around the infundibulum  
* Perifollicular infiltrates around the [[infundibulum]]
* Epidermis is spared or has minimal spongiosis
* [[Epidermis]] is spared or has minimal spongiosis
* Band-like dermal infiltrate of lymphocytes and and histiocytes
* Band-like [[Dermal|derma]]<nowiki/>l infiltrate of [[lymphocytes]] and and [[histiocytes]]
| colspan="2" align="center" style="background:#F5F5F5;" |
| colspan="2" align="center" style="background:#F5F5F5;" |
* Increased risk of :
* Increased risk of :
** Severe viral and bacterial infections
** Severe viral and bacterial infections
** Secondary malignancies, especially lymphomas
** Secondary [[malignancies]], especially lymphomas
* Staging of Mycosis fungoides is based upon:
* Staging of [[Mycosis fungoides]] is based upon:
** Patches
** Patches
** Plaques
** [[Plaques]]
** Skin tumors
** Skin tumors
** Lymphadenopathy
** [[Lymphadenopathy]]
** Erythroderma
** [[Erythroderma]]
** Histology
** [[Histology]]
|-
|-
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Category

Revision as of 16:42, 25 October 2018

Atopic dermatitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Atopic dermatitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography or Ultrasound

CT Scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Atopic dermatitis differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Atopic dermatitis differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Atopic dermatitis differential diagnosis

CDC on Atopic dermatitis differential diagnosis

Atopic dermatitis differential diagnosis in the news

Blogs onAtopic dermatitis differential diagnosis

Directions to Hospitals Treating Atopic dermatitis

Risk calculators and risk factors forAtopic dermatitis differential diagnosis


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Differentiating Atopic Dermatitis from other Diseases

Category Diseases Etiology Inherited Acquired Clinical manifestations Para-clinical findings Associated factors
Demography Symptoms Physical examination
Lab Findings Histopathology
Appearance Itching Fever Tenderness Other Eosinophils Serum IgE
Single/

Multiple

Rash Involved areas Pustule
Skin disorders Atopic dermatitis
  • Epidermal barrier dysfunction
  • Immune dysregulation
+ + Multiple
  • Young children -Scalp, cheeks amd extensor surface
  • Adolescents -flexural areas and buttock-thigh creases
  • Adults - facial involvement and skin flexures
+
  • Infra-auricular and retro-auricular fissuring
  • Nipple eczema
  • White dermographism
  • Perifollicular accentuation
Nl to ↑

(Eosinophilia)

  • Epidermal psoriasiform hyperplasia
  • Marked intercellular edema with spongiotic vesiculation
Allergic contact dermatitis[1] + Any May be multiple after 1-2 days of exposure Erythematous well-demarcated papules Surrounding the area in contact with the offending agent + + Nl to ↑

(Eosinophilia)

Nl
  • Contact with allergens in the past 1-2 days
  • Positive family history
Irritant contact dermatitis[2] + Any, more with occupational exposure Usually single immediately after the exposure Well-demarcated red patch with a glazed surface Any area in contact with the irritant + + Nl Nl
  • Cumulative exposure to irritants
  • Negative hypersensitivity tests
Seborrheic dermatitis
  • Not known
+ Any, onset during the infancy and peak during 3rd-4th decades Multiple
  • Cradle cap - yellowish scales on the scalp
  • Patchy or diffuse greasy scaling with or without a yellow-red base
  • Crusts
Scalp, face, trunk, postauricular, diaper area and axilla + +
  • Infants:
    • Cradle cap (Sclap) - non-inflammatory greasy scales on the scalp
    • Asymptomatic
    • Self resolving
Nl Nl
  • Stress
  • Cold, dry weather can cause flare ups
  • Super infection with bacteria and candida
  • Generalized seborrheic erythroderma in immunodeficient patients
Psoriasis + + Any, 2 peaks of onset 30-39 years and 50-59 years Multiple Well-circumscribed, pink papules and symmetrically distributed cutaneous plaques with silvery scales
  • Scalp
  • Trunk
  • Gluteal cleft
  • Extensor surface of elbows and knees
+ + _ + Nl Nl
  • Smoking
  • Skin trauma
  • Alcohol abuse
  • Stress
  • Cold weather
  • Vitamin D deficiency
  • Drugs
Lichen simplex [3]chronicus + Any, peak at 30-50 years of age Multiple Lichenified and erythematous, pruritic exudative plaque, and excoriations Scalp, head, neck, hands, arms, and genitals areas +
  • Color of plaque varies from yellow to reddish brown
  • Plaque size can vary between 3X6 cm 6X10 cm areas.
Nl Nl
  • Emotional stress
  • Sleep disturbances
  • Dry weather
  • Sweating
  • Excessive dryness
  • Sexual dysfunction
  • Sleep disturbances
  • Depression
  • Dissociative disturbances
Ichthyosis vulgaris[4] + + Usually in infancy Multiple
  • Extensor surfaces of the extremities
  • Scalp
  • Trunk
  • Scales can vary from mild scaling to large, plate (armor)-like scales and thickening of the skin.
Nl Nl
  • Dry and cold weather
  • Increased risk of atopic diseases including asthma, alllergic rhinitis and atopic dermatitis
Nummular dermatitis (discoid eczema) Unknown + Any, two peaks, 6th-7th decade of life in males and 2nd-3rd decade of life in females Multiple
  • Symmetrical coin-shaped erythematous plaques
  • Erosions and excoriations
  • Chronic lesions- central clearing leading to annular lesions
  • Upper and lower extremities
  • Lower trunk
+
  • Chronically lesions result into central clearing leading to annular lesions.
Nl Nl
  • Risk factors:
    • Temperature changes (particularly winter)
    • Emotional stress
    • Dry skin
    • Environmental irritants
    • Recent surgery
    • Medications like topical antibiotic creams and isotretinoin
  • Superinfection with staphylococcus aureus
Netherton's syndrome[5] Autosomal recessive mutations in the serine protease inhibitor of Kazal type 5 gene (SPINK5), encoding LEKTI, a serine protease inhibitor + Affects neonates Multiple
  • Classic triad
    • Congenital ichthyosiform erythroderma
    • Trichorrhexis invaginata
    • Allergic diseases with ↑ serum IgE levels
  • Ichthyosis linearis circumflexa (ILC) - serpiginous plaques with double scale at the margins
  • Diffuse pattern
  • Axillae,
  • Hair
  • Inguinal folds
  • Gluteal cleft
  • Groin
  • Lower legs
+ +
  • Trichorrhexis invaginata (hair involvement):
    • Sparse, short, spike and brittle
    • "Bamboo hair" or "ball and socket deformity" of hair and eyebrows
    • Nodes along the hair shaft
Nl to ↑

(Eosinophilia)

  • Atopic diseases including asthma, atopic dermatitis and allergic rhinitis
  • Systemic and skin superinfections
  • Failure to thrive
  • Electrolyte imbalances, including hypernatremic dehydration
Diseases Etiology Inherited Acquired Demography Single/

Multiple

Rash Involved areas Pustule Itching Fever Tenderness Other WBC Serum IgE Histopathology Associated factors
Infection Molluscum contagiosum Molluscum contagiosum virus inoculation through direct skin contact + Any, peak among children >5 years of age and young adults Multiple
  • Flesh-colored, dome-shaped papules with a central umbilication
  • Lesions are 2-5mm in diameter
+ If molluscum contagiosum is acquired as sexually transmitted disease, it involves, groin and genital region. Nl Nl
  • Often asymptomatic
  • Tender or pruritic skin lesions
  • Self resolve within 2 months
  • Immunocompetent patients present with extensive and severe infections
  • Molluscum contagiosum lesions on the eyelid may lead to follicular or papillary conjunctivitis
Immunologic disorders Dermatitis herpetiformis[6] Autoimmune disorder as a result of gluten sensitivity leading to the formation of IgA antibodies + Any, mean age of disease onset is 2nd-4th decade Multiple
  • Excoriated papules, plaques and vesicles arranged in a clustered fashion
  • Symmetrical
  • Erosions and excoriations
  • Extensor surfaces including arms, knees, and buttocks.
+
  • Oral manifestation such as vesicles and erosion may be present
Nl Nl
  • Intermittent pruritic papules and vesicles
  • Associated small intestine celiac disease with villous atrophy and crypt hyperplasia
  • Abdominal bloating, pain, diarrhea, or constipation
Immune deficiency Wiskott-Aldrich syndrome[7] + Seen almost exclusively in males in infancy Multiple Rash can involve lesions located at the same areas of classical atopic dermatitis:

extensor surfaces of extremities and cheeks or scalp

+ Infants can present with petechiae, prolonged bleeding from umbilicus or circumcision, purpura,hematemesis, melena, epistaxis, hematuria or unusal bruising Nl to ↑

(Eosinophilia)

  • Epidermal psoriasiform hyperplasia
  • Marked intercellular edema with spongiotic vesiculation
  • ↑ serum IgA levels
  • ↑ serum IgE levels
  • Bleeding: severe thrombocytopenia,
  • Eczema - similar to atopic dermatitis
  • Recurrent sino-pulmonary infections
  • Opportunistic infections.
  • Autoimmune diseases
  • Malignancies
Hyper-IgE syndrome[8] + Rare, begin in infancy Multiple
  • Face and scalp
  • Upper trunk and shoulders
  • Buttocks
  • Area behind the ears and around the hairline
+ +
  • Characteristic coarse facies
  • Increased alar width and broad nasal bridge
  • High-arched oral palate
  • Hyperextensible joints
Nl to ↑

(Eosinophilia)

  • Eosinophil-rich infiltration around the hair follicles
  • Cold abscesses
  • Pruritic eczema
  • Allergic diseases
  • Noneruption of permanent teeth
  • Multiple bone fractures and scoliosisis
  • Peripheral T-cell lymphoma
  • Coronary artery aneurysms
Malignancy Mycosis fungoides Clonal expansion of CD4+ memory T cells (CD45RO+) + Mean age is 55- 60 years Multiple
  • Asymmetrical
  • Hips, groin and trunk
+ Nl Nl
Category Diseases Etiology Inherited Acquired Demography Single/

Multiple

Rash Involved areas Pustule Itching Fever Tenderness Other WBC Serum IgE Histopathology Associated factors

References

  1. Nosbaum A, Vocanson M, Rozieres A, Hennino A, Nicolas JF (2009). "Allergic and irritant contact dermatitis". Eur J Dermatol. 19 (4): 325–32. doi:10.1684/ejd.2009.0686. PMID 19447733.
  2. Bains SN, Nash P, Fonacier L (October 2018). "Irritant Contact Dermatitis". Clin Rev Allergy Immunol. doi:10.1007/s12016-018-8713-0. PMID 30293200.
  3. Voicu C, Tebeica T, Zanardelli M, Mangarov H, Lotti T, Wollina U, Lotti J, França K, Batashki A, Tchernev G (July 2017). "Lichen Simplex Chronicus as an Essential Part of the Dermatologic Masquerade". Open Access Maced J Med Sci. 5 (4): 556–557. doi:10.3889/oamjms.2017.133. PMC 5535688. PMID 28785363.
  4. Thyssen JP, Godoy-Gijon E, Elias PM (June 2013). "Ichthyosis vulgaris: the filaggrin mutation disease". Br. J. Dermatol. 168 (6): 1155–66. doi:10.1111/bjd.12219. PMID 23301728.
  5. Chavanas S, Bodemer C, Rochat A, Hamel-Teillac D, Ali M, Irvine AD, Bonafé JL, Wilkinson J, Taïeb A, Barrandon Y, Harper JI, de Prost Y, Hovnanian A (June 2000). "Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome". Nat. Genet. 25 (2): 141–2. doi:10.1038/75977. PMID 10835624.
  6. Kárpáti S (2012). "Dermatitis herpetiformis". Clin. Dermatol. 30 (1): 56–9. doi:10.1016/j.clindermatol.2011.03.010. PMID 22137227.
  7. Buchbinder D, Nugent DJ, Fillipovich AH (2014). "Wiskott-Aldrich syndrome: diagnosis, current management, and emerging treatments". Appl Clin Genet. 7: 55–66. doi:10.2147/TACG.S58444. PMC 4012343. PMID 24817816.
  8. Mogensen TH (April 2013). "STAT3 and the Hyper-IgE syndrome: Clinical presentation, genetic origin, pathogenesis, novel findings and remaining uncertainties". JAKSTAT. 2 (2): e23435. doi:10.4161/jkst.23435. PMC 3710320. PMID 24058807.


Template:WikiDoc Sources